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Immunogenicity and reactogenicity of a combined 
hepatitis A and B vaccine in healthy Chilean subjects 
V. Prado,(‘) S. Riedemann,c2) H. Ibarra,c3) and M. Potinc4) 
Objectives: A combination vaccine against hepatitis A and B provides the opportunity for simultaneous protection 
against both diseases with a single vaccine. This clinical study investigated the reactogenicity and immunogenicity of 
a combined hepatitis A and B vaccine (Twinrix, GlaxoSmithKline Biologicals, Rixensart, Belgium) in healthy Chilean 
adults between 18 and 40 years of age. 
Methods: In total, 345 healthy, seronegative health care workers were enrolled and randomized to three groups who 
received one of three lots of Twinrix on a 0-, l- and 6-month schedules. Blood samples were screened 1 month after 
each dose for anti-HAV and anti-HBs antibodies. Reactogenicity after each dose was assessed using diary cards. 
Results: The nature and incidence of symptoms were similar to those reported for other Twinrix studies. Very few 
symptoms were scored as severe. Upon completion of the vaccination, all subjects had anti-HAV antibodies with 
titers >6000 mIU/mL, and all but one were protected against hepatitis B, with titers ~4000 mIU/mL. 
Conclusions: We have demonstrated the high immunogenicity and tolerance of the combined hepatitis A and B 
vaccine. Combined vaccination has the advantage of offering dual protection with a reduction in the number of 
injections needed, lower associated costs, and a positive impact on compliance. 
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INTRODUCTION 
The hepatitis A and B viruses continue to cause serious 
morbidity and mortality throughout the world. In Latin 
America, there is evidence that the epidemiology of 
hepatitis A virus (HAV) is shifting from a high to an 
intermediate endemicity, with the population susceptible 
to HAV infection changing from children to adolescents 
and adults.’ In Chile, a recent study demonstrated a 
progressive increase in the number of susceptible 
school-age children of medium and low income in 
Santiago.2 A study conducted in Valdivia, Chile, among 
children from different socio-economic backgrounds, 
showed an inversely proportional correlation between 
socio-economic level and seroprevalence of anti-HAV 
antibodies.” A similar study in the same region, among 
adults, confirmed this finding.4 
There are an estimated 6 million hepatitis B (HBV) 
carriers in Latin America, with higher numbers in 
the north of Latin America.5 In Chile, the prevalence of 
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HBV in the general population amounts to 0.6% against 
hepatitis B core antigen and is among the lowest in 
Latin American countries.6-s Although some high-risk 
groups in Chile have been reported as having higher 
rates of HBV infection, in one study in Santiago, 5.9- 
16.1% of a group of health care personnel had at least 
one HBV marker (R. Tapia, personal communication), 
as did 21% in another study of health care personnel.9 
Protection against hepatitis B in high-risk groups is 
clearly favorable from a cost-benefit point of view.‘” In 
the scenario of an epidemiologic shift of hepatitis A in 
Chile, young children and adolescents could also benefit 
from prevention through vaccination. 
With regard to infections caused by hepatitis C virus 
(HCV), the prevalence and the frequency of serotypes 
vary in different regions of the world. Chile is a country 
with low prevalence, as demonstrated by the 0.14-0.3% 
seropositivity range obtained from voluntary blood 
donors in several studies conducted in Santiago de 
Chile.“’ 
Active immunization against hepatitis A and hepa- 
titis B diseases has been available for some time,‘*m14 
and both vaccines have proven to be effective and 
safe.15-17 Although both viruses are very different and 
their modes of transmission differ,i8 a considerable 
similarity in epidemiologic aspects warrants combined 
hepatitis A and B vaccination. Infection by either the 
hepatitis A or B viruses is noticeably more prevalent in 
specific population groups, such as young adolescents 
and health care workers, where high-risk behavior is 
defined by lifestyle or occupation.2J%19 Many of these 
groups that have been shown to be at high risk of 
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infection for both viruses would thus benefit from com- 
bined vaccination. One target group comprises young 
adolescents before they become sexually active, start 
traveling or engage in other risk behavior. At continuous 
risk of infection are health care personnel (mainly 
HBV)20,21 and the staff of daycare centers (HAV).22,23 
People who frequently receive blood-derived products, 
or are on dialysis, have long been known to be at risk for 
hepatitis B infection, but recent studies have shown that 
they might also be at risk for hepatitis A infection.24-26 
Superinfection of hepatitis A in patients with chronic 
hepatitis B, hepatitis C or miscellaneous chronic liver 
disease increases the risk of fulminant hepatic failure or 
hepatocellular carcinoma.27-29 
Combined vaccination reduces the number of inter- 
ventions, and offers greater convenience and logistic 
advantages compared with immunization with the mono- 
valent vaccines. This clinical trial investigated the reacto- 
genicity and immunogenicity of three different lots of 
combined vaccine against hepatitis A and B (Twinrix, 
GlaxoSmithKline Biologicals, Rixensart, Belgium) in 
healthy Chilean adults between 18 and 40 years of age. 
MATERIALS AND METHODS 
Vaccine 
Three different lots of combined hepatitis A/hepatitis 
B vaccine (group 1 lot HAB102D6, group 2 Lot 
HAB123B6, and group 3 lot HAB103B6) containing at 
least 720 ELISA Units of hepatitis A antigen and 20 yg 
of hepatitis B surface antigen were adsorbed onto 0.45 
mg of aluminum in a total volume of 1 mL. Each dose 
of vaccine also contained 2-phenoxyethanol as a 
preservative. 
Study participants 
The trial was performed in two study centers, one 
at Departamento de Microbiologia, Unidad Oriente, 
Faculty of Medicine, University of Chile in Santiago, and 
one at the University Austral of Chile in Valdivia. All 
protocols were approved by the Ethical Committees of 
both universities, and the studies were conducted in 
accordance with the Declaration of Helsinki and its 
amendments, taking in account Good Clinical Practice 
standards. The studies were initiated in June 1997 and 
completed in April 1998. All subjects gave written 
informed consent. Only health care workers were 
included (physicians, medical interns, nurses, dental 
students, and laboratory technicians). All subjects had to 
be seronegative for HAV antibodies, for hepatitis B 
surface (anti-HBs) and hepatitis B core (anti-HBc) anti- 
bodies, and negative for HBs Ag at the time of enrol- 
ment. All subjects were tested for the liver enzymes 
aspartate aminotransferase (AST) and alanine amino- 
transferase (ALT) prior to enrolment. Subjects with 
elevated serum liver enzymes (two-fold normal value of 
45 U/L for ALT and 40 U/L for AST) were excluded. 
Also, subjects with a personal history of chronic liver 
disease, or other significant and persistent illness, or 
treated with any chronic medication, were excluded 
from the study. 
Study design 
This was a double-blind randomized study. Study vaccines 
(each containing 720 EL.U of hepatitis A antigen and 
20 ug of hepatitis B surface antigen, respectively) were 
administered according to 0-, l- and 6-month schedules. 
The subjects were vaccinated intramuscularly in the 
deltoid region. Blood samples were obtained on the day 
of screening and at months 1,2,6 and 7. 
To evaluate reactogenicity, all subjects were asked 
to complete symptom sheets for 4 days, starting on the 
day of vaccination. Solicited local reactions were sore- 
ness, redness and swelling, and general symptoms were 
fever, headache, malaise, fatigue, nausea and vomiting. 
Redness and swelling were scored as grade 1 (1 to 130 
mm), grade 2 (>30 mm), and grade 3 (>30 mm and 
persisting for more than 24 h). Fever was graded as 1 
(37.5-38.O”Q 2 (>38.0-39.O”C) and 3 (>39.O”C). All 
other local and general symptoms were scored as 1 
(adverse experience easily tolerated), 2 (adverse 
experience sufficiently discomforting to interfere with 
daily activities), and 3 (adverse experience which pre- 
vents normal everyday activities). Adverse events were 
reported up to 30 days following vaccination, and serious 
adverse events were reported during the whole study 
period. 
Serology 
Serum liver enzymes (AST and ALT) were tested at 
Laboratorio de Especialidades Medicas, Santiago, Chile. 
Anti-HAV antibodies were measured by screening at 
Laboratorio de Gastroenterologia de1 Hospital Clinic0 
de la Universidad de Chile and Instituto de Micro- 
biologia, Facultad de Ciencias, Universidad Austral de 
Chile.The test used was a commercially available enzyme 
immunoassay kit (HAVAB EIA: Abbott Labortories, 
Abbot Park, IL, USA). Subsequent testing was done 
with the Enzymum Boehringher kit (Boehringer 
Mannheim, Mannheim, Germany) at GlaxoSmithKline 
Biologicals laboratory. The cutoff level of this test 
is 33 mIU/mL. Therefore, subjects with antibody titers 
233 mIU/mL are considered to be seropositives. Sero- 
conversion was defined as cases of negative antibody 
titers who increased to a titer ~33 mIU/mL. Anti-HBs 
antibodies were measured using a commercial RIA test 
(AUSAB, Abbott)at Laboratorio de Gastroenterologia 
de1 Hospital Clinic0 de la Universidad de Chile and 
Instituto de Microbiologia, Facultad de Ciencias, 
Universidad Austral de Chile. Subjects with an anti-HBs 
antibody titer below 1 mIU/mL were considered to 
be seronegative. An increase to 21 mIU/mL was con- 
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sidered a seroconversion, and titers 2 10 mIU/mL were 
considered to be seroprotective. 
Table 1. Incidence of local and aeneral svmotoms 
Statistics LocaP 
Redness 
A descriptive analysis was performed for the reacto- 
genicity and the immunogenicity, with calculation of 
geometric mean titers (GMTs) and 95% confidence 
intervals using the SAS statistical package. Random- 
ization was done using an algorithm of pseudorandom 







Enrolment and study attrition Nausea 
In total, 345 subjects were enrolled, of whom 115 were 
allocated to each study group. Screening for anti-HAV 
(total antibodies) and anti-HBV (anti-HB core, anti- 
HBs and HBs Ag) was performed. In total, 763 subjects 
were tested for anti-HAV (468 in Santiago and 295 
in Valdivia) in order to obtain the 345 seronegatives 
planned to be enrolled. In Santiago, 238/468 (51%) of 
the subjects tested were anti-HAV positive, and in 
Valdivia, 158/295 (53.6% ) were anti-HAV positive. Of 
468 subjects screened for HBV, only six were positive for 
any of the markers. One subject was withdrawn for 
having elevated AST levels at the time of the first dose. 
Later blood tests showed normal transaminase levels. 
A further nine subjects were excluded from the ATP 
analysis for immunogenicity because of blood sampling 
or vaccination timings outside the protocol specifica- 
tions, one subject because of being under the required 
age, four because they had taken medication not fore- 
seen in the protocol, and one because of an adverse 
event unlikely to be related to vaccination (see below); 
three were dropped from the analysis because they 
had abnormally high antibody titers after the first 
vaccination. 
Vomiting 
aExpressed in % 
Over the course of the study, 161 subjects (61 in 
group 1,54 in group 2, and 46 in group 3) reported at 
least one unsolicited adverse event during the 30-day 
follow-up period after each vaccine dose. In total, 272 
unsolicited adverse events (99 in group 1,95 in group 2, 
and 78 in group 3) were reported. Overall, during the 30- 
day follow-up period after each dose, 259 doses (93 in 
group 1,93 in group 2, and 73 in group 3) were followed 
by at least one report of an unsolicited adverse event. 
Only six of these unsolicited events were local reactions 
(four reported as increased temperature at injection site, 
and two as local pruritus). 
One serious adverse event was reported during 
this trial. Nine days after the first vaccination, a subject 
was hospitalized for erythema multiforme. The event 
occurred subsequent to oral antibiotic treatment for 
pharyngitis and tonsillitis, and was therefore determined 
by the investigator as unlikely to be related to vaccina- 
tion. The subject recovered without sequelae. 
Demographics Immunogenicity 
Overall, the mean age was 22.6 years. There were 56.8% 
females (mean age 22.6 years) and 43.2% males (mean 
age 22.6 years). Gender composition and mean ages 
were similar for all three study groups. 
Reactogenicity 
Seropositivity rates and GMTs are presented in Table 2 
(anti-HAV) and Table 3 (anti-HBV). Upon completion 
of the vaccination, all vaccinees had antibodies against 
hepatitis A and all but one subject were protected against 
hepatitis B. The rates of seroconversion and GMTs are 
very similar between all three groups (three different 
lots) included in the study. 
We report data from 1029 doses documented on diary 
cards. The incidence and nature of the symptoms were 
similar for all three groups (lots). Local symptoms were 
more frequently reported than general symptoms. A 
detailed analysis is presented in Table 1. Injection site 
soreness was the most reported local symptom, and 
headache the most frequently encountered general 
symptom. Very few symptoms were scored as severe. 
DISCUSSION 
This study investigated the reactogenicity and immuno- 
genicity of three different lots of GlaxoSmithKline 
Biologicals combined vaccine (Twinrix) against hepatitis 
A and B. All three lots induce a satisfactory immune 
response in this healthy adult cohort, with similar results 
Group 7 Group 2 Group 3 
N 342 342 344 
All 31.0 33.6 34.9 
Grade 3 0 0 0 
All 60.2 60.2 61.9 
Grade 3 0 0.3 0.3 
All 16.1 17.3 18.6 
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Table 2. Anti-HAV immunogenicity 
Anti-HAV response (titer 2 33mlUlmL) 
Groups Timing N % s+ GMT 95% Cl 
1 Ml 106 95.5 444 372-530 
M2 110 99.1 1509 1247-1827 
M6 110 99.1 478 410-557 
M7 111 100 6072 5225-7056 
2 Ml 108 99.1 506 417-614 
M2 109 100 1427 1184-1718 
M6 109 100 488 416-573 
M7 109 100 6669 5812-7652 
3 Ml 106 100 465 377-573 
M2 106 100 1466 1192-1803 
M6 105 100 462 391-545 
M7 105 100 6475 5597-7489 
Vaccination schedule 0, 1 and 6 months. 
M 1, sample obtained 1 month after dose 1 of vaccine; M2, sample 
1 month after dose 2; M6, sample before booster at month 6; M7, 
sample 1 month after booster; % S+, seropositivity rate (anti-HAV 
titer233 mlU/mL); GMT, geometric mean titer; 95% Cl, 95% 
confidence interval. 
Table 3. Anti-HBV immunogenicity 
Anti-HBV (titer response 2 10 mllJlmL) 
Groups Timing N % SP GMT 95% Cl 
1 Ml 111 31.5 9 7-14 
M2 111 80.2 65 45-93 
M6 111 95.5 167 125-223 
M7 111 100 4182 3170-5518 
2 Ml 109 45.9 15 II-20 
M2 109 86.2 92 67-126 
M6 109 98.2 262 201-340 
M7 109 100 6329 4872-8220 
3 Ml 72 it.9 11 B-16 
M2 102 86 61-122 
M6 104 95.2 197 148-260 
M7 105 99.0 4809 3416-6770 
Vaccination schedule 0, 1 and 6 months. 
Ml, sample obtained 1 month after dose 1 of vaccine; M2, sample 
1 month after dose 2; M6, sample before booster at month 6; M7, 
sample 1 month after booster; % SP, seroprotection rate (anti-HBs 
titer210 mlU/mL); GMT, geometric mean titer; 95% Cl, 95% 
confidence interval. 
for all three lots. Comparing our data to those obtained 
with the combined hepatitis A and B vaccine in six 
pivotal clinical trials in 843 healthy subjects,3O we show 
that the seropositivity (for hepatitis A) and sero- 
protection rates(for hepatitis B) and GMTs (for 
hepatitis A and B) fall within the same range for both 
antigens. A study conducted with a monovalent hepatitis 
A vaccine in Valvidia showed similar high seroconversion 
rates for the anti-HAV component, but somewhat lower 
seroconversion rates than with the combined hepatitis A 
and B vaccine used in this study.31 The fact that higher 
anti-HAV titers are obtained with Twinrix compared to 
monovalent vaccination has been reported by other 
investigators.32 
Similarly, the 99-100% seroprotection rate for 
the HBV response is noteworthy, since it is higher than 
that in previously conducted trials with the monovalent 
vaccines. A recently conducted meta-analysis of published 
data for recombinant hepatitis B vaccines showed rates 
of approximately 95% for healthy adults.33 Recently, 
a study was performed with a competitor combined 
hepatitis A and B vaccine, showing a lower immune 
response to the hepatitis B antigen in the vaccine. The 
hepatitis B portion of the vaccine did not produce 
clinically acceptable seropositivity rates 4 weeks after 
the second injection (82.4%). This lack of antibody pro- 
duction was attributed, at least in part, to immunologic 
interference of the vaccine components.34 
Also, the nature and incidence of local and general 
symptoms are similar to those reported for this vaccine. 
Very few of these symptoms were scored as severe.Type, 
incidence and severity of these symptoms following 
administration of the combined vaccine were also similar 
to those observed in clinical trials with the correspond- 
ing monovalent vaccines (Havrix and Engerix-B, Glaxo 
SmithKline).],* Only one serious adverse event was 
reported, and this was unlikely to be related to vaccina- 
tion. 
In conclusion, we have shown high immunogenicity 
and tolerance of the combined hepatitis A and B vaccine 
(Twinrix) in healthy Chilean adults. Combined vaccina- 
tion against both hepatitis A and B has the advantage of 
offering dual protection, with a reduction in the number 
of injections needed, lower associated administration 
costs, and a positive impact on compliance. 
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